This is the authors' abstract. We don't add key points for this paper.
The enzymatic synthesis of coumarin C-glucosides by an engineered C-glycosyltransferase, MiCGTb–GAGM, was explored in vitro and in vivo. MiCGTb–GAGM exhibited a robust C-glucosylation capability toward structurally diverse coumarin derivatives. The whole-cell bioconversion of MiCGTb–GAGM was exploited for large-scale production of coumarin C-glucosides. Two C-glucosides exhibited potent SGLT2 inhibitory activities with IC 50 values at 10 –6 M. These findings provide cost-effective and practical synthetic strategies to generate structurally diverse and novel bioactive coumarin C-glycosides for drug discovery.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: